FGFR2 and cholangiocarcinoma: Our preference for these study types was driven by their capacity to offer the most current and comprehensive insights available in the literature pertaining to the use of FGFR2 inhibitors in the treatment of nonresectable, advanced cholangiocarcinoma. Sources were accessed between April 2023 and August 2023.